Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

RAPT Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- INITIATED PRESTIGE PHASE 2B TRIAL OF OZUREPRUBART IN FOOD ALLERGY - ANNOUNCED POSITIVE TOPLINE DATA FROM PHASE 2 TRIAL IN CHRONIC SPONTANEOUS URTICARIA; RESULTS SHOWED OZUREPRUBART AT BOTH Q8W AND Q12W DOSING HAD COMPARABLE EFFICACY AND SAFETY TO OMALIZUMAB AT Q4W DOSING - COMPLETED $250 MILLION PUBLIC OFFERING TO STRENGTHEN BALANCE SHEET SOUTH SAN FRANCISCO, CALIF., NOV. 06, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT) (RAPT OR THE COMPANY), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025.

RAPT THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

SOUTH SAN FRANCISCO, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT MEMBERS OF THE RAPT MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN NOVEMBER: GUGGENHEIM'S 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE  FIRESIDE CHAT ON TUESDAY, NOVEMBER 11, 2025 AT 3:30 P.M.

RAPT THERAPEUTICS TO PARTICIPATE IN MULTIPLE UPCOMING INVESTOR CONFERENCES

TRIAL INITIATION IN FOOD ALLERGY FOLLOWS PROMISING RESULTS IN PHASE 2 TRIAL IN CHRONIC SPONTANEOUS URTICARIA, ANOTHER IGE-DRIVEN CONDITION RAPT SEEKS TO DEVELOP A DIFFERENTIATED ANTI-IGE THERAPY FOR THE MANY PATIENTS WITH FOOD ALLERGIES SOUTH SAN FRANCISCO, CALIF., OCT. 27, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT IT HAS INITIATED THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PRESTIGE PHASE 2B CLINICAL TRIAL OF OZUREPRUBART (FORMERLY RPT904) IN IGE-MEDIATED FOOD ALLERGY.

RAPT THERAPEUTICS INITIATES PRESTIGE PHASE 2B CLINICAL TRIAL OF OZUREPRUBART (RPT904) IN PATIENTS WITH FOOD ALLERGIES

SOUTH SAN FRANCISCO, CALIF., OCT. 21, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT) (RAPT), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 8,333,334 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $30.00 PER SHARE. IN ADDITION, RAPT HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 1,250,000 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SHARES OF COMMON STOCK ARE BEING OFFERED BY RAPT. THE GROSS PROCEEDS FROM THE OFFERING TO RAPT ARE EXPECTED TO BE APPROXIMATELY $250.0 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT OCTOBER 23, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.

RAPT THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

SOUTH SAN FRANCISCO, CALIF., OCT. 21, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT) (RAPT), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK. IN ADDITION, RAPT EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE TOTAL NUMBER OF SHARES OF COMMON STOCK RAPT IS OFFERING, AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SHARES OF COMMON STOCK ARE BEING OFFERED BY RAPT. THE PROPOSED OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE PROPOSED OFFERING MAY BE COMPLETED OR AS TO THE ACTUAL SIZE OR TERMS OF THE PROPOSED OFFERING.

RAPT THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

- RPT904 AT BOTH Q8W AND Q12W DOSING SHOWED COMPARABLE EFFICACY AND SAFETY TO OMALIZUMAB AT Q4W DOSING- EFFICACY SUSTAINED AT WEEK 16 AFTER A SINGLE DOSE OF RPT904- WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS RELATED TO STUDY DRUG- JEYOU TO ADVANCE RPT904 TO PHASE 3 DEVELOPMENT IN CHINA- RAPT TO DISCUSS PHASE 3 DEVELOPMENT PATH WITH FDA- RAPT TO HOST CONFERENCE CALL AT 8:30 AM ET TODAY SOUTH SAN FRANCISCO, CALIF. AND SHANGHAI, OCT. 20, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, AND SHANGHAI JEYOU PHARMACEUTICAL CO., LTD.

RAPT THERAPEUTICS AND SHANGHAI JEYOU PHARMACEUTICAL ANNOUNCE POSITIVE TOPLINE DATA FROM PHASE 2 TRIAL OF RPT904 (JYB1904) IN CHRONIC SPONTANEOUS URTICARIA

SOUTH SAN FRANCISCO, CALIF., OCT. 19, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE COMPANY PLANS TO REPORT TOPLINE DATA FROM THE PHASE 2 CLINICAL TRIAL OF RPT904 (JYB1904) IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (CSU) CONDUCTED BY ITS PARTNER, SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (JEYOU), FORMERLY CALLED SHANGHAI JEMINCARE PHARMACEUTICAL CO., LTD., IN A PREMARKET PRESS RELEASE AND WEBCAST ON MONDAY, OCTOBER 20, 2025. RAPT WILL HOST A WEBCAST CONFERENCE CALL ACCOMPANIED BY A SLIDE PRESENTATION ON MONDAY, OCTOBER 20, 2025 AT 8:30 A.M. ET. TO JOIN THE CONFERENCE CALL VIA PHONE AND PARTICIPATE IN THE LIVE Q&A SESSION, PLEASE PRE-REGISTER ONLINEHERE TO RECEIVE A TELEPHONE NUMBER AND UNIQUE PASSCODE REQUIRED TO ENTER THE CALL. THE LIVE WEBCAST AND AUDIO ARCHIVE OF THE PRESENTATION MAY BE ACCESSED ON THE RAPT THERAPEUTICS WEBSITE AT HTTPS://INVESTORS.RAPT.COM/EVENTS-AND-PRESENTATIONS.

RAPT THERAPEUTICS TO REPORT TOPLINE DATA FROM PHASE 2 CLINICAL TRIAL OF RPT904 IN CHRONIC SPONTANEOUS URTICARIA (CSU)

SOUTH SAN FRANCISCO, CALIF., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS CLEARED RAPT'S INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO PROCEED TO A PHASE 2B CLINICAL TRIAL OF RPT904 FOR THE TREATMENT OF PATIENTS WITH FOOD ALLERGY.

RAPT THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION TO PROCEED TO PHASE 2B TRIAL OF RPT904 IN FOOD ALLERGY

SOUTH SAN FRANCISCO, CALIF., AUG. 07, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT) (RAPT OR THE COMPANY), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2025.

RAPT THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

SOUTH SAN FRANCISCO, CALIF., JUNE 23, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF SCOTT BRAUNSTEIN, M.D., AND ASHLEY DOMBKOWSKI, PH.D., TO ITS BOARD OF DIRECTORS. DR. BRAUNSTEIN WAS APPOINTED AS A MEMBER OF THE AUDIT COMMITTEE OF THE BOARD AND DR. DOMBKOWSKI WAS APPOINTED AS A MEMBER OF THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE OF THE BOARD. THE COMPANY'S LEAD PRODUCT CANDIDATE RPT904, IS A NOVEL, HALF-LIFE EXTENDED MONOCLONAL ANTIBODY DESIGNED TO BIND FREE HUMAN IMMUNOGLOBIN E (IGE), A KEY DRIVER OF SEVERAL ALLERGIC DISEASES. RPT904 IS CURRENTLY COMPLETING PHASE 2 TRIALS IN CHRONIC SPONTANEOUS URTICARIA AND ASTHMA, AND RAPT PLANS TO INITIATE A PHASE 2 CLINICAL TRIAL FOR FOOD ALLERGY LATER THIS YEAR.

RAPT Therapeutics, Inc.

RAPT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RAPT Therapeutics, Inc.

RAPT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RAPT